Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL-B01D1 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- SystImmune
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BL-B01D1 + pembrolizumab is a combination therapy being developed by Sichuan Baili Pharmaceutical Co., Ltd. for the treatment of advanced biliary tract cancer. BL-B01D1 is a first-in-class bispecific antibody-drug conjugate (ADC) that simultaneously targets the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It consists of the bispecific antibody izalontamab conjugated to ED-04, a novel topoisomerase I inhibitor payload, via a cleavable linker with a drug-to-antibody ratio (DAR) of 8. Pembrolizumab is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, an immune checkpoint. This combination aims to leverage the targeted cytotoxicity of the ADC against tumor cells expressing EGFR/HER3 and the immune-potentiating effects of checkpoint inhibition to improve outcomes in patients with biliary tract malignancies.
- Brand names
- Keytruda
- Other names
- BL-B01D1 plus pembrolizumabBL-B-01D1 plus pembrolizumabBL-B 01D1 plus pembrolizumabizalontamab-ED-04 + pembrolizumab
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)EGFR (Epidermal growth factor receptor)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BL-B01D1 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL-B01D1 + pembrolizumab.